LAS VEGAS, May 11 (Reuters) - William Doyle, a key figure in
Pershing Square (NYSE:) Capital Management's controversial investment in
battered drug company Valeant Pharmaceuticals (NYSE:) , is
leaving the hedge fund, its founder, William Ackman, told
investors on Wednesday.